The age-dependent changes in risk weights of the prognostic factors for multiple myeloma

References

• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427. doi:10.1016/S0140-6736(21)00135-5
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–569. doi:10.1056/NEJMoa01133202
   PubMed Web of Science ®Google Scholar
• Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–1605. doi:10.1200/JCO.2009.25.2114
   PubMed Web of Science ®Google Scholar
• Liu J, Liu W, Mi L, et al. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136. doi:10.1186/s13045-019-0807-5
   PubMed Web of Science ®Google Scholar
• Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood. 2021;137(1):16–19. doi:10.1182/blood.2019004309
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi:10.1002/ajh.25791
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the myeloma XI trial. Leukemia. 2020;34(2):604–612. doi:10.1038/s41375-019-0595-5
   Web of Science ®Google Scholar
• An G, Xu Y, Shi L, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99(2):353–359. doi:10.3324/haematol.2013.088211
   PubMed Web of Science ®Google Scholar
• International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757. doi:10.1046/j.1365-2141.2003.04355.x
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. doi:10.1200/JCO.21.02614
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695. doi:10.1182/blood-2010-10-299487
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655. doi:10.1097/00000421-198212000-00014
   PubMed Web of Science ®Google Scholar
• Blagden SP, Charman SC, Sharples LD, et al. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022–1027. doi:10.1038/sj.bjc.6601231
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–2074. doi:10.1182/blood-2014-12-615187
   PubMed Web of Science ®Google Scholar
• Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–233. doi:10.1038/s41375-019-0539-0
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–921. doi:10.3324/haematol.2016.162693
   PubMed Web of Science ®Google Scholar
• Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):e154–ee66. doi:10.1016/S2352-3026(18)30220-5
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039–4047. doi:10.1182/blood-2007-03-081018
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980–987. doi:10.3324/haematol.2012.075051
   PubMed Web of Science ®Google Scholar
• Chretien ML, Hebraud B, Cances-Lauwers V, et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica. 2014;99(7):1236–1238. doi:10.3324/haematol.2013.098608
   PubMed Web of Science ®Google Scholar
• Heegaard NH. beta(2)-microglobulin: from physiology to amyloidosis. Amyloid. 2009;16(3):151–173. doi:10.1080/13506120903151775
   PubMed Web of Science ®Google Scholar
• Nakazato T, Hagihara M, Sahara N, et al. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. Ann Hematol. 2021;100(11):2745–2754. doi:10.1007/s00277-021-04592-y
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Gonzalez B, de la Rubia J, et al. Further psychometric validation of the GAH scale: Responsiveness and effect size. J Geriatr Oncol. 2017;8(3):211–215. doi:10.1016/j.jgo.2016.12.008
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101(9):1110–1119. doi:10.3324/haematol.2016.148189
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol. 2013;31(22):2806–2809. doi:10.1200/JCO.2012.46.2598
   PubMed Web of Science ®Google Scholar
• Barth P, Giri S, Reagan JL, et al. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. Am J Hematol. 2021;96(1):14–22. doi:10.1002/ajh.25996
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. doi:10.1038/s41408-020-0311-8
   PubMed Web of Science ®Google Scholar
• O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222–230. doi:10.1111/bjh.15261
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917. doi:10.1056/NEJMoa1402551
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596. doi:10.1016/S1470-2045(21)00466-6
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021;21(11):785–798. doi:10.1016/j.clml.2021.06.005
   PubMed Web of Science ®Google Scholar
• Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066–1077. doi:10.1038/s41375-021-01488-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519–4529. doi:10.1182/blood-2011-06-358812
   PubMed Web of Science ®Google Scholar